The funding round was led by UCL Technology Fund, Parkwalk, and Innovate UK to support sensor development and clinical trials.
"Coronary heart disease is endemic worldwide but far too often the decision to implant a stent is based on sub-optimal information. Our technology addresses the ‘grey zone’ of patients where the requirement for a stent is currently difficult to determine. By using advanced optical sensing technology, we hope to significantly improve the accuracy of current treatments, saving healthcare costs and preventing unnecessary operations for patients that could be treated with medicines."
The round was led by BGF with participation from Parkwalk, Cambridge Enterprise, and Cambridge Innovation Capital.
"Parkwalk are delighted to continue to support the ground breaking technology from Dr Ken Smith’s laboratory at Addenbrookes, which enables the prognosis of IBD and an earlier clinical decision as to the correct drug treatment. This will significantly improve clinical outcomes and enhance patient welfare. The team at PredictImmune have done a magnificent job in productising the technology and are now taking the tests on their commercial pathway. We look forward to seeing the platform extended to benefit clinical outcomes in further diseases."
The Series B round was led by Kureha Corporation and will accelerate commercial rollout and market expansion.
"We’re delighted to welcome our new corporate and VC investors from Japan and China, as well as having the continued strong support of our existing investors, who together form a world-class group that will help scale CTT quickly to exploit the market opportunity for its technology. CTT has grown rapidly over the last several years, and we’re looking forward to being able to continue executing on our growth plan and sharpening our commercialization focus within the consumer electronics, automotive and industrial markets. The partners we have and the injection of new capital means we can expect to enable our customers to begin rolling out the technology at scale in the near future."
Parkwalk led the Series A financing to support product development and commercialisation.
"This funding marks the start of the next phase in Paragraf’s growth. I am extremely proud of the young team at Paragraf who have collectively delivered the early strategy milestones with great skill. This next phase will allow Paragraf to make these truly game-changing technologies a reality. Paragraf is continually seeking like-minded collaborative development, production and commercial partners to accelerate the delivery of the many exciting electronics technology opportunities graphene has to offer."
The Southampton radiation detection specialist secured £3m from existing backers to fund its US expansion.
"We are delighted to have secured this latest round of growth funding, which has demonstrated continued support from existing investors and will enable us to take full advantage of the global growth opportunities we are presented with. Our range of market leading radiation detection technologies provide real world solutions to real world challenges and expanding our operations in the US is a key tenet of our growth strategy."
